Although dose–response studies were not conducted for each drug tested, the dose of β-Pro7 Ang III [33–35] or C21 [53,54] used in this study had demonstrated anti-fibrotic effects in other models of injury-induced fibrosis, whereas the dose of pirfenidone used had prevented [43] or therapeutically reduced [39] BLM-induced lung fibrosis in mice. This evidence concerns the gene AGT and pulmonary fibrosis.